Figures computed from official regulatory filings — .
Analysttarget 12 USD (+1999900%) · consensus 5/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0% · institutions 0% · short 0.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Scopus BioPharma Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
31 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lamstein Joshua Rtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Greenspan Ira Scotttrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Hopper Paul | Other | n/a (No price was disclosed in the filing) | SEC |
| Hopper Paul | Other | n/a (No price was disclosed in the filing) | SEC |
| Greenspan Ira Scotttrack record | Buy | $541.2 | conv 23 | SEC |
| Greenspan Ira Scotttrack record | Buy | $3.9K | conv 26 | SEC |
| Lamstein Joshua Rtrack record | Buy | $1K | conv 27 | SEC |
| Lamstein Joshua Rtrack record | Buy | $980 | conv 28 | SEC |
| Greenspan Ira Scotttrack record | Buy | $2.2K | conv 24 | SEC |
| Greenspan Ira Scotttrack record | Buy | $232.5 | conv 23 | SEC |
| Greenspan Ira Scotttrack record | Buy | $1.7K | conv 24 | SEC |
| Greenspan Ira Scotttrack record | Buy | $8.1K | conv 31 | SEC |
| Lamstein Joshua Rtrack record | Buy | $3.2K | conv 29 | SEC |
| Greenspan Ira Scotttrack record | Buy | $4.3K | conv 27 | SEC |
| Greenspan Ira Scotttrack record | Buy | $4.1K | conv 28 | SEC |
| Lamstein Joshua Rtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lamstein Joshua Rtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lamstein Joshua Rtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Greenspan Ira Scotttrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Lamstein Joshua Rtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Greenspan Ira Scotttrack record | Buy | $1.9K | conv 24 | SEC |
| Lamstein Joshua Rtrack record | Buy | $7.1K | conv 53Unusual size | SEC |
| Greenspan Ira Scotttrack record | Buy | $908 | conv 23 | SEC |
| Greenspan Ira Scotttrack record | Buy | $5.2K | conv 34 | SEC |
| Greenspan Ira Scotttrack record | Buy | $4.8K | conv 28 | SEC |